Galapagos NV (GLPG)
Pre-Market:
| Previous Close | 37.27 |
| Open | 36.51 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 36.17 - 36.62 |
| 52 Week Range | 36.17 - 72.11 |
| Volume | |
| Avg. Volume | 278,396 |
| Market Cap | 2.411B |
| Beta (5Y Monthly) | 0.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.66 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.27 |
- GlobeNewswire
Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting
Publication of annual report for financial year 2022Annual Shareholders’ Meeting proposed resolutions include re-appointment of Board members and appointment of new statutory auditor Mechelen, Belgium; 23 March 2023, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2022 and announces its Annual Shareholders’ Meeting, to be held on Tuesday 25 April 2023, at 2:00 p.m. (CET), at the registered office of the company. T
- GlobeNewswire
Galapagos increases share capital through subscription right exercises
Mechelen, Belgium; 20 March 2023, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 61,560 new ordinary shares on 20 March 2023, for a total capital increase (including issuance premium) of EUR 1,769,850.00. In accordance with Belgian transparency legislation1, Galapagos also wishes to note that its total share capital currently amounts to EUR 356,444,938.61, the total number of
- GlobeNewswire
Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Six presentations demonstrate Galapagos’ commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib, an oral, once daily, JAK1 preferential inhibitor) will be presentedSELECTIONLTE showed that filgotinib maintained a consistent safety profile; symptomatic remission rates and health-related quality of life (HRQoL) improved in patients with moderate to severe active ulcerative colitis (UC)
